LHRH antagonists vs LHRH agonists: Which is more beneficial in prostate cancer therapy?

Daniel Keizman, Mario A. Eisenberger

Research output: Contribution to journal › Comment/debate › peer-review

ASJC Scopus subject areas

@article{d4b732e818334b06bdb5fc4f0d6c8a3b,

title = "LHRH antagonists vs LHRH agonists: Which is more beneficial in prostate cancer therapy?",

author = "Daniel Keizman and Eisenberger, {Mario A.}",

year = "2009",

month = jun,

day = "1",

language = "English (US)",

volume = "23",

pages = "631--632",

journal = "ONCOLOGY",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "7",

}

TY - JOUR

T1 - LHRH antagonists vs LHRH agonists

T2 - Which is more beneficial in prostate cancer therapy?

AU - Keizman, Daniel

AU - Eisenberger, Mario A.

PY - 2009/6/1

Y1 - 2009/6/1

UR - http://www.scopus.com/inward/record.url?scp=67650872893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650872893&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 19626831

AN - SCOPUS:67650872893

SN - 0890-9091

VL - 23

SP - 631

EP - 632

JO - ONCOLOGY

JF - ONCOLOGY

IS - 7

ER -